These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19248293)

  • 21. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 22. Predicting the potential benefits of early initiation of ART: time to do a trial to find out.
    Phillips AN; Emery S
    Curr Opin HIV AIDS; 2009 May; 4(3):165-6. PubMed ID: 19532044
    [No Abstract]   [Full Text] [Related]  

  • 23. Early initiation of ART produces better clinical outcomes.
    Clin Infect Dis; 2009 Apr; 48(8):iii. PubMed ID: 19301458
    [No Abstract]   [Full Text] [Related]  

  • 24. Side effects. Using metabolomics for predicting side effects.
    TreatmentUpdate; 2005; 17(5):11-2. PubMed ID: 17219662
    [No Abstract]   [Full Text] [Related]  

  • 25. [New therapies in the management of seropositive persons].
    Riou JM
    Soins; 2009 Apr; (734):54. PubMed ID: 19475834
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
    Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP
    Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Szczech LA
    Curr Opin HIV AIDS; 2009 May; 4(3):167-70. PubMed ID: 19532045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
    J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
    [No Abstract]   [Full Text] [Related]  

  • 30. Update on new antiretroviral drugs. An interview with Harold Kessler, M.D. by Matt Sharp.
    Kessler H
    Posit Aware; 2007; 18(6):22-4. PubMed ID: 18074429
    [No Abstract]   [Full Text] [Related]  

  • 31. Alterations in acute-phase proteins among HIV-1 infected persons receiving generic HAART in southern India.
    Sundaram M; Srinivas CN; Shankar EM; Balakrishnan P; Solomon S; Kumarasamy N
    J Infect; 2009 Jun; 58(6):465-7. PubMed ID: 19443037
    [No Abstract]   [Full Text] [Related]  

  • 32. Canvassing CROI.
    Kresge KJ; McEnery R
    IAVI Rep; 2009; 13(1):4-8. PubMed ID: 20214276
    [No Abstract]   [Full Text] [Related]  

  • 33. HIV baby boom: following perinatally-infected children. How is their disease different in adulthood?
    AIDS Alert; 2009 Nov; 24(11):125-6. PubMed ID: 19960607
    [No Abstract]   [Full Text] [Related]  

  • 34. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Vogel M; Rockstroh JK
    Curr Opin HIV AIDS; 2009 May; 4(3):171-5. PubMed ID: 19532046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox.
    Abzug MJ; Pelton SI
    J Infect Dis; 2009 Apr; 199(8):1109-11. PubMed ID: 19265480
    [No Abstract]   [Full Text] [Related]  

  • 36. Pipeline update: short notes on new anti-HIV drugs in development.
    Proj Inf Perspect; 2006 Oct; (42):11-6. PubMed ID: 17162806
    [No Abstract]   [Full Text] [Related]  

  • 37. [HAART influences the lipids].
    Behrens G
    MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
    [No Abstract]   [Full Text] [Related]  

  • 38. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective].
    Wepner U
    MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of depression in predicting antiretroviral adherence in Ugandan parents and their children initiating HAART in the MTCT-plus family treatment model: commentary on Jayne Byakika-Tusiime et al. 2009.
    Nakimuli-Mpungu E; Musisi S
    AIDS Behav; 2009 Oct; 13(5):969-72. PubMed ID: 19662522
    [No Abstract]   [Full Text] [Related]  

  • 40. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: authors' reply.
    Crum-Cianflone NF; Hullsiek KH; Marconi V; Weintrob A; Ganesan A; Barthel RV; Fraser S; Agan BK
    AIDS; 2009 Aug; 23(13):1791-2. PubMed ID: 19684484
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.